Oriol Mirallas MD· @DrMirallas · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
#AACR26
New frontiers in oncology
Zoldonrasib (KRASG12D-ON) #NSCLC #KRASG12D
Dr. Reiss
@ucdavis
ORR 52%
DCR 93%, mPFS 11.1m, OS NR
N/V 43%, diarrhea 30%
New player #KRASG12D
@RevMedicines
By
@danieltanmd
Puts into context very nicely
@OncoAlert
@AACR
Heat 50 · 34 likes · 3 replies · 13 reposts
Source: Oriol Mirallas MD · x.com